Pomegranate.
Plant polyphenols.
A variable pathway.

Memory was measured at baseline, six months and twelve months using the Brief Visuospatial Memory Test-Revised and Buschke Selective Reminding Test. The main published conclusion concerns the ability to benefit from repeated exposure to visual information.

Only one of six cognitive measures showed a significant between-group difference. The juice group remained statistically stable on that learning measure while placebo declined. Other visual-memory and verbal-memory outcomes did not show significant group differences. It is more accurate to describe preservation on a selected endpoint than improved memory in general.

The paper reports 261 randomized and 200 completers (98 juice, 102 placebo). Its allocation and dropout descriptions do not reconcile cleanly across sections, so this page uses the explicitly reported total and final-completer counts rather than calculating arm-specific attrition. No effect-size chart is drawn from an abstract or a conference report.

The studied juice provided 368 mg punicalagins, 93 mg anthocyanins, 29 mg ellagic acid and 98 mg other tannins per daily serving. These chemical amounts, not the word pomegranate alone, help define the intervention. The trial did not test a liposomal extract or Pro+.

The extract supplied 75 mg punicalagin per daily dose. Fourteen participants were randomized to each arm; only eight extract and ten placebo participants completed. This attrition and the short duration limit confidence.

Reported urolithin A increases were 6.6% with extract and 1.1% with placebo (p = 0.13). The result did not establish a between-group benefit. These percentages are not the fraction of participants who became urolithin producers. Exact uncertainty intervals are not supplied with this summary, so they are not converted into a benefit chart.

Propionate increased in the extract group, but acetate did not reach significance; overall microbial diversity did not change. Multiple exploratory microbial and metabolite analyses do not demonstrate improved symptoms or disease outcomes. A rise in a microbial metabolite is not automatically a health benefit.

The study was designed around blood exposure and producer status, not strength, mobility, disease risk or how people felt. The abstract reports that only about 40% significantly converted precursors after juice intake, while direct supplementation produced higher and more consistent exposure.

That population-level finding is not a prediction of what one person will produce from a particular extract. It also cannot prove the benefits of the Pro+ blend or show that Akkermansia solves the conversion bottleneck. The investigators had commercial involvement in direct urolithin A development, which is relevant to interpreting the comparison.

The present page does not borrow finished-urolithin A muscle or mitochondrial trial outcomes as pomegranate-extract outcomes. The interventions are chemically and pharmacokinetically different.

The trial paired memory testing with functional MRI during cognitive tasks. It reported improvement on a verbal-memory measure and greater task-related fMRI activity in juice recipients compared with placebo.

Brain activation is a physiological response, not a direct measure of improved daily functioning. The small sample and multiple assessments make this preliminary. Its short-term positive verbal finding should be read alongside the later, larger trial’s narrower result, rather than counted as confirmation of every memory claim.